Global Gastrointestinal Partnering 2012-2018: Latest Deal Trends, Players and Financials - ResearchAndMarkets.com

September 17, 2018

DUBLIN--(BUSINESS WIRE)--Sep 17, 2018--The “Global Gastrointestinal Partnering 2012-2018: Deal trends, players and financials” report has been added to ResearchAndMarkets.com’s offering.

The Global Gastrointestinal Partnering 2012-2018: Deal trends, players and financials report provides an understanding and access to the Gastrointestinal partnering deals and agreements entered into by the world’s leading healthcare companies.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Gastrointestinal disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Gastrointestinal deals.

The report presents financial deal terms values for Gastrointestinal deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

Report scope

Trends in Gastrointestinal dealmaking in the biopharma industry since 2012 Analysis of Gastrointestinal deal structure Access to headline, upfront, milestone and royalty data The leading Gastrointestinal deals by value since 2012

Available deals are listed by:

Company A-Z Headline value Stage of development at signing Deal component type Specific therapy target

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Gastrointestinal dealmaking

Chapter 3 - Financial deal terms for Gastrointestinal partnering

Chapter 4 - Leading Gastrointestinal deals and dealmakers

Chapter 5 - Gastrointestinal contract document directory

Chapter 6 - Gastrointestinal dealmaking by therapeutic target

For more information about this report visit https://www.researchandmarkets.com/research/bj3w33/global?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180917005744/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Gastrointestinal Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/17/2018 04:05 PM/DISC: 09/17/2018 04:05 PM


Update hourly